Experience with the HeartMate II Left Ventricular Assist Device in Patients Older than 60 Years

  • Zumrut T. Demirozu Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • Andre Critsinelis Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • William E. Cohn
  • Rajko Radovancevic Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • Jonathan Ho Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • Ruben Hernandez Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • Jeffrey Adam Morgan Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA
  • O Howard Frazier Division of Cardiothoracic Transplantation and Circulatory Support Baylor College of Medicine Houston, Texas, USA

Abstract

Background: Advanced age is a relative contraindication for heart transplantation, but no age cutoff has been defined for patients receiving mechanical circulatory support.

Methods: Between November 1, 2003 and November 1, 2012, we implanted the HeartMate II (HMII) left ventricular assist device (LVAD) in 319 patients. One hundred seven patients (89 men, 18 women) were over 60 years old (mean, 66 ± 4 years; range, 61-78 years) and received the HMII as a bridge to transplantation (n = 45) or as destination therapy
(n = 62). We evaluated their experience by performing a retrospective analysis.

Results: Seventy-two patients had ischemic cardiomyopathy, and 34 had idiopathic cardiomyopathy. Three patients (2.8%) already had a HeartMate XVE LVAD; 54 (50.5%) were receiving intra-aortic balloon pump support; 52 (48.6%) had undergone a previous cardiac procedure; and 9 (8.4%) had received renal replacement therapy (RRT) (continuous venovenous hemofiltration, hemodialysis, or both) before HMII implantation. The median duration of HMII support was 313 days (range, 1-3339 days). After device implantation, 36 patients (33.6%) had gastrointestinal bleeding, 24 (23%) required RRT, 18 (17.5%) had ventricular arrhythmias, and 24 (22.4%) had LVAD-related infections, and 9 (8.4%) had right ventricular failure requiring mechanical support, and 28 (26.2%) had neurologic complications. The actual survival rate was 69% at 6 months, 63% at 1 year, and 54% at 2 years. Eighty-one patients died; 9 are still receiving HMII support; and 17 are alive after heart transplantation.

Conclusions: Older patients can benefit from LVAD therapy, and advanced age should not preclude LVAD implantation.

References

Adamson RM, Stahovich M, Chillcott S, et al. 2011. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J Am Coll Cardiol 57(25):2487-95.

Dang NC, Topkara VK, Kim BT, Mercando ML, Kay J, Naka Y. 2005. Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation. J Thorac Cardiovasc Surg 130(5):1302-9.

Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH. 2011. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant 30(2):182-7.

Deng MC, Loebe M, El-Banayosy A, et al. 2001. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation 103(2):231-7.

Drews T, Stepanenko A, Dandel M, Buz S, Lehmkuhl HB, Hetzer R. 2010. Mechanical circulatory support in patients of advanced age. Eur J Heart Fail 12(9):990-4.

Genovese EA, Dew MA, Teuteberg JJ, et al. 2010. Early adverse events as predictors of 1-year mortality during mechanical circulatory support. J Heart Lung Transplant 29(9):981-8.

Holman WL, Kormos RL, Naftel DC, et al. 2009. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 28(1):44-50.

Huang R, Deng M, Rogers JG, et al. 2006. Effect of age on outcomes after left ventricular assist device placement. Transplant Proc 38(5):1496-8.

John R, Naka Y, Park SJ, et al. 2014. Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. J Thorac Cardiovasc Surg 147(2):581-9; discussion 589.

Joyce DL, Conte JV, Russell SD, Joyce LD, Chang DC. 2009. Disparities in access to left ventricular assist device therapy. J Surg Res 152(1):111-7.

Jurmann MJ, Weng Y, Drews T, Pasic M, Hennig E, Hetzer R. 2004. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg 25(4):610-8.

Kirklin JK, Naftel DC, Kormos RL, et al. 2011. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 30(2):115-23.

Kohmoto T, Osaki S, Johnson MR, et al. 2009. Improved outcomes after ventricular assist device implantation in patients older than 60 years of age. J Heart Lung Transplant 28(2 suppl):S134.

Kwon MH, Moriguchi JD, Plunkett MD, et al. 2008. Impact of age on outcomes of ventricular assist devices utilized as bridge to cardiac transplantation. J Heart Lung Transplant 27(2 suppl):S120.

Magnussen C, Bernhardt AM, Ojeda FM, et al. 2018. Gender differences and outcomes in left ventricular assist device support: The European Registry for Patients with Mechanical Circulatory Support. J Heart Lung Transplant 37(1):61-70.

Morgan JA, John R, Lee BJ, Oz MC, Naka Y. 2004. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 77(3):859-63.

Ochiai Y, McCarthy PM, Smedira NG, et al. 2002. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 106(12 suppl 1):I198-202.

Rose EA, Gelijns AC, Moskowitz AJ, et al. 2001. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345(20):1435-43.

Sandner SE, Zimpfer D, Zrunek P, et al. 2009. Age and outcome after continuous-flow left ventricular assist device implantation as bridge to transplantation. J Heart Lung Transplant 28(4):367-72.

Schenk S, McCarthy PM, Blackstone EH, et al. 2006. Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. J Thorac Cardiovasc Surg 131(2):447-54.

Stepanenko A, Potapov EV, Jurmann B, et al. 2010. Outcomes of elective versus emergent permanent mechanical circulatory support in the elderly: a single-center experience. J Heart Lung Transplant 29(1):61-5.

Published
2019-03-08
How to Cite
Demirozu, Z., Critsinelis, A., Cohn, W., Radovancevic, R., Ho, J., Hernandez, R., Morgan, J., & Frazier, O. (2019). Experience with the HeartMate II Left Ventricular Assist Device in Patients Older than 60 Years. The Heart Surgery Forum, 22(2), E124-E130. https://doi.org/10.1532/hsf.2297
Section
Articles